US Patent Office Rejects Three More Axonics' Challenge To Medtronic Patents - Medtronic (NYSE:MDT), Axonics (NASDAQ:AXNX)

The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed three Medtronic plc MDT patents related to its InterStim sacral neuromodulation device family challenged by Axonics Inc AXNX.
These patents relate to recharging technology.
Today's decisions complete the review process initiated by Axonics to challenge the validity of the seven patents involved in the IP infringement case brought by Medtronic.
Cumulatively, the PTAB has now affirmed claims in all seven of the Medtronic patents.
Medtronic said it will now request that the U.S. District Court in the Central District of California lift the stay on an intellectual property infringement case and resume proceedings.
Earlier this month, the appeals board rejected challenges to three other InterStim patents from Axonics.
Price Action: MDT stock traded 0.30% higher at $129.30, and AXNX stock traded 0.07% lower at $69.73 on the last check Thursday.